Modern approaches to therapy of allergic rhinosinusitis
https://doi.org/10.21518/2079-701X-2016-18-64-68
Abstract
The issue of allergic rhinosinusitis therapy is extremely urgent as of today. This is related, on the one hand, to the intense growth of the disease incidence, on the other hand, with aggravation of the allergic process course, addition of infectious complications, development of polysensitization. The approach to diagnostics of this disease must be consistent and complex. The accurate analysis of clinical manifestations and rational use of diagnostics tests are extremely important for the correct diagnosing. Allergic rhinitis is IgE-mediated primary chronic inflammatory disease of the mucous tunic of the nasal cavity. The basis of prescription of the rational therapy of this disease is clear understanding of pathogenic mechanisms of its development. Surgical therapy is indicated for these patients in the majority of cases, but it doesn’t have any pathogenic role.
About the Authors
P. A. Kochetkov
Sechenov First Moscow State Medical University
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. M. Svistushkin
Sechenov First Moscow State Medical University
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
I. Y. Meytel
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Bousquet J. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008 Apr, 63(Suppl 86): 8-160.
2. Крюков А.И., Гурбанов Ф.А. Патогенетическая терапия аллергического риносинусита на современном этапе. Российская оториноларингология, 2010, 5(48): 25-29.
3. Лопатин А.С., Гамов В.П. Острый и хронический риносинусит: этиология, патогенез, клиника, диагностика и принципы лечения: Учебное пособие для системы послевузовского проф. образования врачей. М.: МИА, 2011. 72 с.
4. Никифорова Г.Н., Волкова К.Б., Свистушкин В.М. Место и значение современных антигистаминных препаратов в лечении аллергического ринита. РМЖ, 2015, 23: 1395-1398.
5. Лопатин А.С. Ринит: руководство для врачей. М.: ГЭОТАР-Медиа, 2010. 417 с.
6. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol, 2005, 116: 377-383.
7. Jones NS, Smith PA, Carney AS, Davis A. The prevalence of allergic rhinitis and nasal symptoms in Not- tingham. Clin Otolaryngol, 1998, 23: 547-554.
8. Magnan A, Romanet S, Vervloet D. Rhinitis, nasosinusalpoliposis and asthma: clinical aspects. The Nose and Lung Diseases. Ed. by B Wallaert, P Chanez, P Godard. Eur. Resp. Monograph. 2001: 101-115.
9. ARIA. Аллергический ринит и его влияние на бронхиальную астму. Аллергология. Приложение, 2001, 3: 43-56.
10. Izquierdo-Domínguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr. Allergy Asthma Rep, 2013 Apr, 13(2): 142-141.
11. Kimihiro Okubo et al. Japanese Guideline for Allergic Rhinitis. Allergology International, 2011, 60: 171-189.
12. Татаурщикова Н.С. Дезлоратадин – современное эффективное средство лечения аллергического ринита. Фарматека, 2013, 10: 66-68.
13. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in hu mans. Fundam Clin Pharmacol, 2004, 18(4): 399-411.
14. Limon L, Kockler DR. Desloratadine: a nonsedating antihistamine. Ann Pharmacother, 2003, 37(2): 237-246.
15. Wu RL et al. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol, 2004, 135(4): 313-318.
16. Genovese A et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy, 1997, 27(5): 559-567.
17. Ring J. et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebocontrolled study. Int J Dermatol, 2001, 40(1): 72-76.
18. Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria results of four postmarketing surveillance studies. Clin Drug Investig, 2010, 30(2): 109-122.
Review
For citations:
Kochetkov PA, Svistushkin VM, Meytel IY. Modern approaches to therapy of allergic rhinosinusitis. Meditsinskiy sovet = Medical Council. 2016;(18):64-68. (In Russ.) https://doi.org/10.21518/2079-701X-2016-18-64-68
Views:
902
Email this article 